NasdaqGS:ALNYBiotechs
Assessing Alnylam After Stock Surges 100% on RNAi Momentum in 2025
If you own Alnylam Pharmaceuticals stock or are thinking about starting a position, you might be feeling a mix of excitement and caution right now. With shares closing recently at $465.89 and riding a year-to-date gain of nearly 100%, Alnylam has easily outpaced the broader biotech sector. That surge is even more impressive over the long term, with a five-year return topping 250%. It is clear the market has taken notice.
What has fueled this momentum? Beyond general enthusiasm for biotech’s...